Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.

Li CJ, Yu Q, Yu P, Zhang QM, Ding M, Liu XJ, Yu DM

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association16 May 2014Cited by 17 (Europe PMC)

PMID24838155DOI10.1055/s-0034-1374586PepBankPUB-24838155

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c more than saxagliptin over 24 weeks.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c more than saxagliptin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change versus saxagliptin
Study
n = 178
Comparator
Saxagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.5%
liraglutide 1.2 mg
HbA1c change
−1.23%
saxagliptin
Source sentences
Summary
Over the 24-week treatment period, greater lowering of mean of HbA1c was achieved with 1.2 mg liraglutide (-1.50%, 95% CI [-1.67, -1.34]) than with saxagliptin (-1.23%, 95% CI [-1.36, -1.11]) and vildagliptin (-1.25%, 95% CI [-1.37, -1.13]).
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815501
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c more than vildagliptin over 24 weeks.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c more than vildagliptin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change versus vildagliptin
Study
n = 178
Comparator
Vildagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.5%
liraglutide 1.2 mg
HbA1c change
−1.25%
vildagliptin
Source sentences
Summary
Over the 24-week treatment period, greater lowering of mean of HbA1c was achieved with 1.2 mg liraglutide (-1.50%, 95% CI [-1.67, -1.34]) than with saxagliptin (-1.23%, 95% CI [-1.36, -1.11]) and vildagliptin (-1.25%, 95% CI [-1.37, -1.13]).
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815502
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, the percentage reaching HbA1c below 7.0% did not differ significantly between liraglutide, saxagliptin and vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, similar numbers reached HbA1c below 7.0% with liraglutide, saxagliptin or vildagliptin.
Peptide
Liraglutide
Outcome
No significant changeProportion reaching HbA1c below 7.0%
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant between-group difference of percentages of subjects who reached a target HbA1c<7.0%
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815503
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, significantly more subjects reached HbA1c of 6.5% or lower with liraglutide than with saxagliptin or vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, more people reached HbA1c of 6.5% or lower with liraglutide than with saxagliptin or vildagliptin.
Peptide
Liraglutide
Outcome
IncreaseProportion reaching HbA1c of 6.5% or lower
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
but significantly more subjects with liraglutide achieved HbA1c≤6.5% compared with saxagliptin and vildagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815504
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide reduced fasting blood glucose more than saxagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide cut fasting blood sugar more than saxagliptin.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose reduction versus saxagliptin
Study
n = 178
Comparator
Saxagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
FBG reduction
2.23 mmol/L
liraglutide
FBG reduction
1.83 mmol/L
saxagliptin
Source sentences
Summary
The mean reduction of FBG value from baseline was 2.23 mmol/L with liraglutide, much greater than 1.83 mmol/L with saxagliptin (p=0.013)
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815505
06HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, the fasting blood glucose reduction with liraglutide was similar to that with vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide and vildagliptin cut fasting blood sugar by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeFasting blood glucose reduction versus vildagliptin
Study
n = 178
Comparator
Vildagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
FBG reduction
2.23 mmol/L
liraglutide
FBG reduction
2.03 mmol/L
vildagliptin
Source sentences
Summary
The mean reduction of FBG value from baseline was 2.23 mmol/L with liraglutide, much greater than 1.83 mmol/L with saxagliptin (p=0.013), but similar to 2.03 mmol/L with -vildaglitpin group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815506
07HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide reduced 2-hour postprandial glucose more than saxagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide cut after-meal blood sugar more than saxagliptin.
Peptide
Liraglutide
Outcome
DecreasePostprandial blood glucose reduction versus saxagliptin
Study
n = 178
Comparator
Saxagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
P2BG change
−4.8 mmol/L
liraglutide
P2BG change
−3.56 mmol/L
saxagliptin
Source sentences
Summary
As to the P2BG value, greater reductions was found with liraglutide (-4.80 mmol/L) than -3.56 mmol/L with saxagliptin (p=0.000) and -3.57 mmol/L with vildagliptin (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815507
08HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide reduced 2-hour postprandial glucose more than vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide cut after-meal blood sugar more than vildagliptin.
Peptide
Liraglutide
Outcome
DecreasePostprandial blood glucose reduction versus vildagliptin
Study
n = 178
Comparator
Vildagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
P2BG change
−4.8 mmol/L
liraglutide
P2BG change
−3.57 mmol/L
vildagliptin
Source sentences
Summary
As to the P2BG value, greater reductions was found with liraglutide (-4.80 mmol/L) than -3.56 mmol/L with saxagliptin (p=0.000) and -3.57 mmol/L with vildagliptin (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815508
09HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide reduced body weight more than saxagliptin or vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide led to more weight loss than saxagliptin or vildagliptin.
Peptide
Liraglutide
Outcome
DecreaseBody weight reduction
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Body weight change
−6 kg
liraglutide
Source sentences
Summary
Moreover, greater mean reductions of body weight and BMI with liraglutide (-6.0 kg and -2.1 kg/m(2)) were achieved than with saxagliptin and vildagliptin (both p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815509
10HumanRandomized controlled trialEfficacy outcome
In Chinese adults with poorly controlled type 2 diabetes, liraglutide reduced BMI more than saxagliptin or vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, liraglutide lowered BMI more than saxagliptin or vildagliptin.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
BMI change
−2.1 kg/m2
liraglutide
Source sentences
Summary
Moreover, greater mean reductions of body weight and BMI with liraglutide (-6.0 kg and -2.1 kg/m(2)) were achieved than with saxagliptin and vildagliptin (both p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815510
11HumanRandomized controlled trialSafety outcome
In Chinese adults with poorly controlled type 2 diabetes, hypoglycemia incidence was low and similar in the liraglutide, saxagliptin and vildagliptin groups.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, low blood sugar was rare and similar across the three drugs.
Peptide
Liraglutide
Outcome
No significant changeIncidence of hypoglycemia
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycemia was recorded low and similar in each treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815511
12HumanRandomized controlled trialSafety outcome
In Chinese adults with poorly controlled type 2 diabetes, nausea was more common with liraglutide than with saxagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, nausea was more common with liraglutide than with saxagliptin.
Peptide
Liraglutide
Outcome
IncreaseNausea versus saxagliptin
Study
n = 178
Comparator
Saxagliptin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Nausea incidence
27%
liraglutide
Nausea incidence
3.2%
saxagliptin
Source sentences
Summary
Nausea was more common with liraglutide (27%) than with saxagliptin (3.2%)
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815512
13HumanRandomized controlled trialSafety outcome
In Chinese adults with poorly controlled type 2 diabetes, nausea was more common with liraglutide than with vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, nausea was more common with liraglutide than with vildagliptin.
Peptide
Liraglutide
Outcome
IncreaseNausea versus vildagliptin
Study
n = 178
Comparator
Vildagliptin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Nausea incidence
27%
liraglutide
Nausea incidence
5.2%
vildagliptin
Source sentences
Summary
Nausea was more common with liraglutide (27%) than with saxagliptin (3.2%) and vildagliptin (5.2%)
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815513
14HumanRandomized controlled trialSafety outcome
In Chinese adults with poorly controlled type 2 diabetes, other adverse events did not differ significantly between liraglutide, saxagliptin and vildagliptin.
In plain wordsIn Chinese adults with poorly controlled type 2 diabetes, other side effects were similar across the three drugs.
Peptide
Liraglutide
Outcome
No significant changeOther adverse events
Study
n = 178
Comparator
Saxagliptin and vildagliptin
Outcome group
Adverse events · Whole body
Studied dose
1.2 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
but no significant between-group difference was reported in other AEs
1 context sentence(design, population, supporting numbers)
Summary · context
A total 178 patients completed the trial who had been randomly assigned to add-on once daily liraglutide (1.2 mg/day injected subcutaneously), to saxagliptin (5 mg once daily) or to vildagliptin (50 mg twice daily).
Report a problemFND-2483815514

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.